Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial
Authors:
Open Access
- 28 March 2022
- journal article
- research article
- Published by Elsevier in The Lancet Haematology
- Vol. 9 (4) , e262-e275
Abstract
No abstract availableKeywords
Funding Information
- Blood Cancer UK (14044)
- Cancer Research UK (C27995/A9609)
- Cancer Research UK (C27995/A21019)
This publication has 16 references indexed in Scilit:
- Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trialLeukemia, 2016
- CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic valueHematology, 2012
- CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual diseaseHaematologica, 2011
- Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemiaBlood, 2011
- Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008Leukemia, 2009
- Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemiaHaematologica, 2009
- Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemiaBlood, 2009
- CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapyBlood, 2008